Similar articles

• Why most gene expression signatures of tumors have not been useful in the clinic.

  Koscielny S. Koscielny S. Sci Transl Med. 2010 Jan 13;2(14):14ps2. doi: 10.1126/scitranslmed.3000313. Sci Transl Med. 2010. PMID: 20371465
• Development and validation of gene expression profile signatures in early-stage breast cancer.

  Desmedt C, Sotiriou C, Piccart-Gebhart MJ. Desmedt C, et al. Cancer Invest. 2009 Jan;27(1):1-10. doi: 10.1080/07357900802574710. Cancer Invest. 2009. PMID: 19191098 Review. No abstract available.
• Cancer biology: signatures guide drug choice.

  Downward J. Downward J. Nature. 2006 Jan 19;439(7074):274-5. doi: 10.1038/439274a. Nature. 2006. PMID: 16421553 No abstract available.
• Run batch effects potentially compromise the usefulness of genomic signatures for ovarian cancer.

  Baggerly KA, Coombes KR, Neeley ES. Baggerly KA, et al. J Clin Oncol. 2008 Mar 1;26(7):1186-7; author reply 1187-8. doi: 10.1200/JCO.2007.15.1951. J Clin Oncol. 2008. PMID: 18309960 No abstract available.
• "Stemness" genomics law governs clinical behavior of human cancer: implications for decision making in disease management.

  Glinsky GV. Glinsky GV. J Clin Oncol. 2008 Jun 10;26(17):2846-53. doi: 10.1200/JCO.2008.17.0266. J Clin Oncol. 2008. PMID: 18539963 Review.